Atopic Dermatitis Clinical Trials in Camp Hill, Pennsylvania

4 studies are recruiting for atopic dermatitis in Camp Hill, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study Evaluating TRIV-573 in Atopic Dermatitis

    The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573. Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo). The study duratio…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Triveni Bio Site #1, Camp Hill, Pennsylvania
    Locations
    17 in total
    Run by
    Triveni Bio

    See if you can join NCT07782333 on ClinicalTrials.gov

  2. A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

    The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin. The study is seeking partic…

    Stage
    Phase 3
    Ages
    12 and older
    Site
    Best Skin Research, LLC, Camp Hill, Pennsylvania
    Locations
    32 in total
    Run by
    Pfizer

    See if you can join NCT07783425 on ClinicalTrials.gov

  3. A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

    This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

    Stage
    Phase 2
    Ages
    18 to 65
    Site
    Best Skin Research, LLC, Camp Hill, Pennsylvania
    Locations
    85 in total
    Run by
    Apollo Therapeutics Ltd

    See if you can join NCT07599813 on ClinicalTrials.gov

  4. A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

    The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)

    Stage
    Phase 1
    Ages
    18 and older
    Site
    DermDox Centers for Dermatology, Camp Hill, Pennsylvania
    Locations
    3 in total
    Run by
    Brexogen Inc.

    See if you can join NCT06055361 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.